NCT07117227 Validation of RCC Predicting Model With Emulated-target Trial
| NCT ID | NCT07117227 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Renal Cell Carcinoma (Kidney Cancer) |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,700 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,700 participants in total. It began in 2025-09-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years of age; * Diagnosis of primary renal cell carcinoma before and during the surgery; * Received radical nephrectomy/nephron-sparing surgery. Exclusion Criteria: * Subjects with severely missing clinical information; * History of other malignant tumors. * Recurrence observed before first postoperative follow-up. * Discontinue the adjuvant treatment within in the first two course because of severe adverse react.
Contact & Investigator
Yongyue Wei, master
STUDY DIRECTOR
Peking University Health Science Center
Frequently Asked Questions
Who can join the NCT07117227 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Renal Cell Carcinoma (Kidney Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07117227 currently recruiting?
Yes, NCT07117227 is actively recruiting participants. Contact the research team at chenjiyuan@pku.edu.cn for enrollment information.
Where is the NCT07117227 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07117227 clinical trial?
NCT07117227 is sponsored by Peking University Third Hospital. The principal investigator is Yongyue Wei, master at Peking University Health Science Center. The trial plans to enroll 4,700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.